Is a complete GRCE research report available?

No complete published report is available for Grace Therapeutics, Inc. (GRCE) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Grace Therapeutics, Inc. (GRCE)

NASDAQ: GRCE · USD

$2.07

-0.01 (-0.5%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first GRCE analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	33.7M
Net income (ttm)	-7.8M
EPS (ttm)	-$0.47
Shares out	16.3M
Volume	296,903
Beta	0.37
Price target	$6.05	+192.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -7.8M
EPS (ttm): -$0.47
Market cap: 33.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GRCE indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001444192
Company name	Grace Therapeutics, Inc.
Country	United States
Country code	US
Cusip	00439U104
Employees	5
Employees Change	-1%
Employees Change Percent	-16.67
Enterprise value	$16.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US00439U1043
Last refreshed	2026-07-31
Market cap	$33.7M
Market cap category	Nano-Cap
Price	$2.07
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	GRCE
Website	https://www.gracetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.13%
FCF yield	-26.33%
P/B ratio	0.52x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-7.8M
Net Income Growth Years	3%
Profit Per Employee	$-1.6M
ROA	-9.99
Roa5y	-10.5
ROCE	-17.17
ROE	-11.94
Roe5y	-21.36
ROIC	-10.61

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-30.11%
Cagr1y	-30.55%
Cagr3y	-5.84%
Cagr5y	-37.66%
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$66.7M
Cash	$17M
Current Assets	$17.4M
Current Liabilities	$2.1M
Debt	$0
Equity	$63.9M
Liabilities	$2.8M
Long Term Assets	$49.3M
Long Term Liabilities	$612,000
Net Cash	$17M
Net Cash By Market Cap	$50.4
Net Cash Growth	-23.3%
Net Debt Equity	$-0.27
Tangible Book Value	$14.6M
Tangible Book Value Per Share	$0.91
WACC	6.29

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.1
Net Working Capital	$-1.7M
Quick ratio	7.92
Working Capital	$15.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-36.6%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-97.22%
1Y total return	-30.54%
200-day SMA	3.2
3Y total return	-16.53%
50-day SMA	2.35
50-day SMA vs 200-day SMA	50under200
5Y total return	-90.58%
All Time High	2,016
All Time High Change	-99.9%
All Time High Date	2013-07-24
All Time Low	1.72
All Time Low Change	20.35%
All Time Low Date	2023-09-22
ATR	0.16
Beta	0.37
Beta1y	0.82
Beta2y	1.17
Ch YTD	-40.17
High	2.08
High52	5.18
High52 Date	2026-04-02
High52ch	-60.04%
Low	1.95
Low52	1.79
Low52 Date	2026-04-23
Low52ch	15.64%
Ma50ch	-11.84%
Premarket Change Percent	-1.92
Premarket Price	$2.04
Premarket Volume	101
Price vs 200-day SMA	-35.31%
RSI	29.5
RSI Monthly	39.95
RSI Weekly	38.65
Sharpe ratio	-0.14x
Sortino ratio	-0.1
Total Return	-36.6%
Tr YTD	-40.17
Tr1m	-10%
Tr1w	-11.91%
Tr3m	-1.43%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	2
Analyst Price Target Top	$8
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.18
Earnings Revenue Estimate	545,000x
Operating Income	$-11.1M
Price target	$6.05
Price Target Change	$190
Price Target Change Top	$286

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13,592,015%
Float Percent	83.52%
Shares Insiders	15.72%
Shares Institutions	26.39%
Shares Out	16,274,026
Shares Qo Q	1.9%
Shares Yo Y	36.6%
Short Float	12%
Short Ratio	6.18
Short Shares	10.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-9.7M
Adjusted OCF	-9,667,000
Average Volume	238,052.75x
Bv Per Share	3.99
Ch10y	-97.22
Ch1m	-10
Ch1w	-11.91
Ch1y	-30.54
Ch3m	-1.43
Ch3y	-16.53
Ch5y	-90.58
Ch6m	-41.03
Change	-0.48%
Change From Open	1.47
Close	2.08
Days Gap	-1.92
Depreciation Amortization	7,000
Dollar Volume	614,589.2
Earnings Date	2026-08-10
Earnings Time	bmo
EBIT	$-11.1M
EBITDA	$-11.1M
EPS	$-0.47
F Score	0
FCF	$-8.9M
FCF EV Yield	-53.08x
FCF Per Share	$-0.54
Financing CF	3,713,000
Fiscal Year End	March
Founded	2,002
Goodwill	8,138,000
Income Tax	$-1.7M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-06-18
Last Report Date	2026-03-31
Last Split Date	2023-07-10
Last Split Type	Reverse
Last10k Filing Date	2026-06-18
Ma150	3.21
Ma150ch	-35.49%
Ma20	2.38
Ma20ch	-13.03%
Net CF	-5,156,000
Next Earnings Date	2026-08-11
Open	2.04
Optionable	Yes
Position In Range	92.31
Ppne	1,000
Pre Close	2.08
Price Date	2026-07-30
Ptbv Ratio	2.3
Relative Volume	1.25x
Share Based Comp	798,000
Tr6m	-41.03%
Us State	New Jersey
Volume	296,903

Grace Therapeutics, Inc. (GRCE)

Coverage state: Market snapshot only — no published research

Generate the first GRCE analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · GRCE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GRCE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GRCE

Frequently asked questions